# FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

> **NCT01410630** · — · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 66 (actual)

## Conditions studied

- Lymphoma
- Lymphoma, Non-Hodgkin
- Large B Cell Diffuse Lymphoma

## Interventions

- **DIAGNOSTIC_TEST:** FLT-PET/CT
- **DIAGNOSTIC_TEST:** FDG-PET/CT
- **DRUG:** FLT

## Key facts

- **NCT ID:** NCT01410630
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-07
- **Primary completion:** 2019-10-04
- **Final completion:** 2019-10-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410630, "FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01410630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*